Quote:
Originally Posted by DanL
Whether it is primary or secondary or therapy related seems to be less relevant to the outcome. The historical context is that T-MDS/AML or S-MDS/AML patients typically have more or worse chromosomal abnormalities than deNovo.
.
|
Hey Dan!
Good stuff. I need to do some reading up on this. What you are finding makes perfect sense, when you think about it.
Take care!
Greg
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at
www.greghankins.com